GSK PLC Sponsored ADR (GSK)
(Delayed Data from NYSE)
$43.55 USD
+0.54 (1.26%)
Updated Sep 16, 2024 04:00 PM ET
After-Market: $43.55 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$43.55 USD
+0.54 (1.26%)
Updated Sep 16, 2024 04:00 PM ET
After-Market: $43.55 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
Zacks News
Can Biotech ETFs Continue to Soar in 2020?
by Neena Mishra
We discuss coronavirus, cancer drugs, gene therapies, crispr and related biotech stocks & ETFs.
Glaxo (GSK) Lags Q4 Earnings & Revenue Estimates, Stock Down
by Zacks Equity Research
Glaxo (GSK) misses on earnings and sales in the fourth quarter. The company expects earnings to decline in 2020.
Theravance Pipeline Strong, Dependence on Yupelri a Concern
by Zacks Equity Research
Theravance's (TBPH) COPD drug Yupelri witnesses a strong adoption while its pipeline programs make a steady progress. However, high reliance on Yupelri for revenues is a concern.
Gilead (GILD) Q4 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Gilead's (GILD) earnings fall short of estimates but sales beat the same in the fourth quarter of 2019.
Glaxo (GSK) Misses Earnings & Revenue Estimates in Q4
by Zacks Equity Research
Glaxo misses both earnings and sales estimates in the fourth quarter of 2019. The company initiates separation program to split itself into two standalone units. Stock down.
What's in Store for Innoviva (INVA) This Earnings Season?
by Zacks Equity Research
Strong demand for Glaxo's Trelegy Ellipta is likely to have driven royalties for Innoviva (INVA) in the fourth quarter, which is partially offset by lower royalties from Relvar/Breo Ellipta.
Is a Disappointment in Store for Glaxo's (GSK) Q4 Earnings?
by Zacks Equity Research
Glaxo's (GSK) Vaccines and Respiratory segments are likely to have driven sales in the fourth quarter.
Will Strong HIV Sales Drive Gilead's (GILD) Q4 Earnings?
by Zacks Equity Research
Investors will focus on the performance of the HIV franchise and the uptake of Yescarta along with pipeline updates, when Gilead (GILD) reports fourth-quarter 2019 results.
Pfizer (PFE) Lags Q4 Earnings & Sales Estimates, Stock Down
by Zacks Equity Research
Pfizer (PFE) misses estimates for fourth-quarter earnings and sales. Loss of patent protection for key drug Lyrica in 2019 hurts sales significantly.
Epizyme Gets FDA Nod for Lead Drug in Epithelioid Sarcoma
by Zacks Equity Research
Epizyme (EPZM) gets a significant boost with the approval of Tazverik (tazemetostat) for the treatment of metastatic or locally advanced epithelioid sarcoma.
Pharma Stock Roundup: J&J's Mixed Q4, Roche & Novartis' New Drugs Approval in EU
by Kinjel Shah
J&J (JNJ) announces mixed Q4 results. Roche's (RHHBY) lymphoma drug, Polivy and Novartis' (NVS) Mayzent for secondary progressive multiple sclerosis (SPMS) get approval in Europe.
Glaxo's Multiple Myeloma Candidate Gets FDA's Priority Review
by Zacks Equity Research
Glaxo's (GSK) BLA for belantamab mafodotin gains the FDA priority review status to treat heavily pre-treated patients with relapsed or refractory multiple myeloma.
Should Value Investors Pick GlaxoSmithKline (GSK) Stock?
by Zacks Equity Research
Is GlaxoSmithKline (GSK) a great pick from the value investor's perspective right now? Read on to know more.
Clovis Rubraca sNDA for Prostate Cancer Gets Priority Review
by Zacks Equity Research
Clovis' (CLVS) sNDA seeking label expansion of Rubraca to include BRCA-mutant advance prostate cancer gets priority review from the FDA. Stock up.
Emergent (EBS) Posts Preliminary '19 Results, Gives 2020 View
by Zacks Equity Research
Emergent (EBS) narrows revenue view for 2019 and expects a consistent rise in Narcan nasal spray sales during 2020.
Glaxo Files Marketing Application for Fostemsavir in Europe
by Zacks Equity Research
Glaxo (GSK) submits an MAA in Europe for its investigational candidate fostemsavir, which is being developed for treating HIV-1 infection in heavily pre-treated adult HIV patients.
Gilead (GILD) Inks License Deal with Xencor for HIV Candidate
by Zacks Equity Research
Gilead Sciences (GILD) entered into a technology license agreement with Xencor for use of XmAb antibody technologies in investigational agents for HIV.
Merck's Keytruda Gets FDA Nod for High-Risk Bladder Cancer
by Zacks Equity Research
Merck's (MRK) Keytruda gets FDA's approval to treat certain patients with high-risk, non-muscle invasive bladder cancer.
Merck's Keytruda Misses One of Two Goals in Lung Cancer Study
by Zacks Equity Research
Merck's (MRK) phase III first-line SCLC study fails to meet one of the two primary endpoints. It signs an oncology collaboration with Taiho Pharmaceutical and Astex Pharmaceuticals.
Glaxo (GSK) Shares Continue to Witness Upside: Here's Why
by Zacks Equity Research
Glaxo's (GSK) successful product launches, increasing focus on the oncology area, and positive pipeline and regulatory updates are driving the stock.
3 Reasons Why You Should Buy Eli Lilly (LLY) Stock in 2020
by Zacks Equity Research
Here are three reasons, which investors may consider while investing in Lilly's (LLY) stock.
Myriad Genetics' Cancer Companion Diagnostic Test Gets FDA Nod
by Zacks Equity Research
Myriad Genetics (MYGN) expands the use of BRACAnalysis CDx as a companion diagnostic test for metastatic pancreatic cancer with the receipt of the FDA clearance.
AstraZeneca's Lynparza Gets FDA Nod for Pancreatic Cancer
by Zacks Equity Research
AstraZeneca (AZN) and Merck's Lynparza becomes the first PARP inhibitor to get approval for treating pancreatic cancer in the United States.
How GlaxoSmithKline (GSK) Stock Stands Out in a Strong Industry
by Zacks Equity Research
GlaxoSmithKline (GSK) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Here's Why You Should Hold on to Thermo Fisher Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Thermo Fisher (TMO) on its stellar segmental performance.